Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

44806 ARTÍCULOS , VIENDO DEL 61 AL 75

[A case of Parkinsonism possibly associated with long-term methamphetamine use]

Aso Y, Masuda T, Sumi K, Takahata K, Kimura N.

Rinsho Shinkeigaku. 2026 Oct 22;66(10):712-715. doi: 10.5692/clinicalneurol.cn-002266. Epub 2026 Sep 19.

Microplastics as Emerging Neurotoxins: Brain Accumulation, Neuroinflammation, and Neurodegeneration Risk

Sophian A, Asmariani, Ismayani E.

J Biochem Mol Toxicol. 2026 Oct;40(10):e71070. doi: 10.1002/jbt.71070.

Recent advances in metabolism and applications of medium-chain triglycerides in neurodegenerative diseases.

Ye X, Borges K, Chang M, Fu X, Zhang T

Crit Rev Food Sci Nutr. 2026:1-13. doi: 10.1080/10408398.2026.2737560.

Mast Cells in Neuroimmune Interactions: Mechanisms, Pathophysiological Roles, and Therapeutic Implications

Hasan A, Asfour AAR, Qaba H, Al-Sharabi AA, Asfoor A, Mohammed S, Al-Adhreai A, Güner S, ALSaeedy M.

Mol Neurobiol. 2026 Sep 26;63(1):925. doi: 10.1007/s12035-026-06173-4.

Polyamines across neurodegenerative proteinopathies

Ranxhi B, LeWitt PA, Tsou WL, Todi SV.

Neurobiol Dis. 2026 Nov;230:107629. doi: 10.1016/j.nbd.2026.107629. Epub 2026 Sep 26.

Ambroxol in Gaucher disease and GBA1-related Parkinson disease: an updated systematic review

Lipiński P, Jezela-Stanek A, Tylki-Szymańska A.

Acta Neurol Belg. 2026 Sep 27. doi: 10.1007/s13760-026-03202-w. Online ahead of print.

[Under the spell of valproic acid]

Sveinsson OA, Hilmarsson A, Thors B.

Laeknabladid. 2026 Oct;112(10):445-447. doi: 10.17992/lbl.2026.10.914.

Genetic architecture and molecular pathogenesis of Parkinson's disease: emerging mechanisms and therapeutic targets

Yildirim S.

Metab Brain Dis. 2026 Sep 28;41(1):228. doi: 10.1007/s11011-026-01998-3.

Advances in the management of depression in Parkinson's disease: A narrative review on vortioxetine, hyperbaric oxygen, and physical activity

Mesquita I, Araújo B, Soares-Guedes C, Teixeira C, Caridade-Silva R, Summavielle T, Pinto L, Domingos J, Godinho C, Teixeira FG.

Biomed Pharmacother. 2026 Sep 28;204:119954. doi: 10.1016/j.biopha.2026.119954. Online ahead of print.

Parkinson, melanoma, and the dermatologist

Heymann WR.

J Am Acad Dermatol. 2026 Sep 28:S0190-9622(26)03640-6. doi: 10.1016/j.jaad.2026.09.090. Online ahead of print.

Oral Environment and Aspiration Pneumonia Risk in Parkinson's Disease: A Narrative Review and Conceptual Framework

Furuya H, Longnecker D, Almazan E, Hinojosa O, Rochester T, Carnaby G.

J Oral Rehabil. 2026 Sep 28. doi: 10.1111/joor.70326. Online ahead of print.

Continuous infusion therapy after deep brain stimulation in Parkinson's disease: indications, outcomes, and patient selection

Hero M, Papić E, Grozdanić N, Vuletić V.

J Neural Transm (Vienna). 2026 Sep 28. doi: 10.1007/s00702-026-03300-2. Online ahead of print.

Lifestyle medicine for neuroprotection: evidence and implementation in Asian contexts

Kim S, Chung SJ, Yoon S, Bloem BR, Postma E, Kim R, Fujioka S, Nagaishi Y, Phokaewvarangkul O, Park KW, Tan EK, Khongprasert S, Youn J.

J Neural Transm (Vienna). 2026 Sep 28. doi: 10.1007/s00702-026-03294-x. Online ahead of print.

Multiple Accessory Pathways in Children: Electrophysiological Features and Catheter Ablation Outcomes

Torun EG, Özdemiroğlu N, Yıldız A, Ömeroğulları Z, Ekşi MA, Koca S.

Pacing Clin Electrophysiol. 2026 Sep 28. doi: 10.1111/pace.70455. Online ahead of print.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias